Ductal Carcinoma in Situ disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DCT002 MIFTS: 55	Ductal Carcinoma in Situ Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ ¹² ²⁹ ¹⁵

Noninfiltrating Intraductal Carcinoma ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0060074

UMLS ⁷³ C0007124

Sources

Summaries for Ductal Carcinoma in Situ

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and breast reconstruction. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Nolvadex and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Increased cell death HMECs cells and cellular

Wikipedia : ⁷⁶ Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Sources

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)

#	Related Disease	Score	Top Affiliating Genes
1	comedo carcinoma	32.6	ERBB2 ESR1
2	breast reconstruction	31.4	BRCA1 BRCA2
3	mammographic density	31.0	CYP19A1 ESR1 PGR
4	gynecomastia	30.7	AR CYP19A1 ESR1 PGR
5	papillary carcinoma	30.3	CDH1 ERBB2 MUC1 PGR
6	bilateral breast cancer	30.1	BRCA1 BRCA2 ERBB2 ESR1 PGR
7	breast disease	30.1	ERBB2 ESR1 KRT5 PGR TP53
8	lobular neoplasia	30.1	BRCA1 CDH1 ERBB2 ESR1 MUC1
9	papilloma	29.4	CCND1 KRT14 KRT5 KRT8 TP53
10	squamous cell carcinoma	27.0	AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
11	breast ductal carcinoma	26.9	AR BRCA1 CCND1 CDH1 EGFR ERBB2
12	breast cancer	21.2	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
13	scirrhous adenocarcinoma	11.0	ERBB2 PGR
14	breast apocrine carcinoma	11.0	ERBB2 PGR
15	endometrium carcinoma in situ	11.0	PGR TP53
16	vulvar syringoma	11.0	ESR1 PGR
17	lung leiomyoma	11.0	ESR1 PGR
18	breast intraductal proliferative lesion	11.0	EGFR ERBB2
19	endometrial clear cell adenocarcinoma	11.0	ESR1 TP53
20	vulvar benign neoplasm	10.9	ESR1 PGR
21	breast papillomatosis	10.9	CCND1 ERBB2
22	trigonitis	10.9	ESR1 PGR
23	brain ependymoma	10.9	EGFR TP53
24	vulvar leiomyoma	10.9	ESR1 PGR
25	glassy cell carcinoma of the cervix	10.9	ERBB2 ESR1 PGR
26	rare adenocarcinoma of the breast	10.9	AKT1 TP53
27	hereditary site-specific ovarian cancer syndrome	10.9	BRCA1 BRCA2
28	vestibular gland benign neoplasm	10.9	ESR1 PGR TP53
29	bartholin's gland adenoma	10.9	ESR1 PGR TP53
30	gallbladder squamous cell carcinoma	10.9	ERBB2 TP53
31	gastric papillary adenocarcinoma	10.9	ERBB2 TP53
32	uterine body mixed cancer	10.9	ERBB2 PGR TP53
33	intracystic papillary adenoma	10.8	EGFR ERBB2 PGR
34	bartholin's gland benign neoplasm	10.8	ESR1 PGR TP53
35	progesterone-receptor negative breast cancer	10.8	EGFR ERBB2 PGR
36	cervical carcinosarcoma	10.8	ESR1 PGR TP53
37	adenosarcoma	10.8	ESR1 PGR TP53
38	non-proliferative fibrocystic change of the breast	10.8	CCND1 ERBB2 TP53
39	oral leukoplakia	10.8	CCND1 ERBB2 TP53
40	papillary serous adenocarcinoma	10.7	BRCA1 PGR TP53
41	tuberculous salpingitis	10.7	BRCA1 BRCA2 ERBB2
42	predominantly cortical thymoma	10.7	ESR1 KRT14 PGR
43	nosophobia	10.7	BRCA1 BRCA2 PGR
44	cancerophobia	10.7	BRCA1 BRCA2 PGR
45	adenomyosis	10.7	ESR1 PGR PTGS2
46	ovarian serous cystadenocarcinoma	10.7	ERBB2 PGR TP53
47	barrett's adenocarcinoma	10.7	ERBB2 PTGS2 TP53
48	salivary gland cancer	10.7	AKT1 EGFR ERBB2
49	uterine corpus cancer	10.7	ERBB2 ESR1 PGR TP53
50	protoplasmic astrocytoma	10.7	PTGS2 TP53

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:

Sources

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell death HMECs cells	GR00103-A-0	9.1	BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

⁴⁶ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.49	CCND1 BRCA2 CDH1 AR AKT1 BRCA1
2	growth/size/body region	MP:0005378	10.48	CCND1 BRCA2 CDH1 AR AKT1 BRCA1
3	digestive/alimentary	MP:0005381	10.47	CCND1 BRCA2 CDH1 BRCA1 AR KRT14
4	cardiovascular system	MP:0005385	10.46	CCND1 CDH1 AKT1 BRCA1 AR ERBB2
5	endocrine/exocrine gland	MP:0005379	10.46	CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
6	homeostasis/metabolism	MP:0005376	10.46	BRCA1 CCND1 BRCA2 AR AKT1 ESR1
7	hematopoietic system	MP:0005397	10.44	CCND1 BRCA2 AKT1 BRCA1 AR KRT14
8	integument	MP:0010771	10.44	CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
9	immune system	MP:0005387	10.42	CCND1 BRCA2 CDH1 AR AKT1 BRCA1
10	behavior/neurological	MP:0005386	10.4	BRCA1 CCND1 BRCA2 AR AKT1 ESR1
11	mortality/aging	MP:0010768	10.4	BRCA1 CCND1 BRCA2 AR AKT1 ESR1
12	embryo	MP:0005380	10.37	BRCA2 AR AKT1 BRCA1 ERBB2 ESR1
13	adipose tissue	MP:0005375	10.28	BRCA1 AR AKT1 ESR1 KRT14 TP53
14	neoplasm	MP:0002006	10.27	CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
15	limbs/digits/tail	MP:0005371	10.18	BRCA1 BRCA2 AR ESR1 ERBB2 PGR
16	muscle	MP:0005369	10.18	BRCA1 AR AKT1 ESR1 ERBB2 PGR
17	normal	MP:0002873	10.18	CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
18	nervous system	MP:0003631	10.17	BRCA1 CCND1 BRCA2 AR AKT1 ESR1
19	craniofacial	MP:0005382	10.15	CCND1 AR ERBB2 KRT14 KRT5 TP53
20	liver/biliary system	MP:0005370	10.11	AR AKT1 ESR1 KRT8 TP53 PTGS2
21	reproductive system	MP:0005389	10.06	CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
22	no phenotypic analysis	MP:0003012	9.95	ESR1 PGR KRT5 TP53 PTGS2 EGFR
23	renal/urinary system	MP:0005367	9.86	BRCA1 AR ESR1 TP53 PTGS2 CLDN7
24	pigmentation	MP:0001186	9.8	BRCA1 AR KRT14 TP53 EGFR CYP19A1
25	respiratory system	MP:0005388	9.61	BRCA1 CCND1 AKT1 ESR1 ERBB2 KRT14
26	skeleton	MP:0005390	9.4	BRCA1 CCND1 BRCA2 AR AKT1 ESR1

Sources

Drugs & Therapeutics for Ductal Carcinoma in Situ

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Nolvadex ¹⁸ ⁴⁹	TAMOXIFEN CITRATE	AstraZeneca	October 1998
FDA Label: Nolvadex Disease/s that Drug Treats:Breast Cancer Indications and Usage: ¹⁸ Metastatic Breast Cancer:NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. Inpremenopausal women with metastatic breast cancer, NOLVADEX is an alternative tooophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumorsare estrogen receptor positive are more likely to benefit from NOLVADEX therapy.Adjuvant Treatment of Breast Cancer:NOLVADEX is indicated for the treatment of node-positive breast cancer in women followingtotal mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In someNOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four ormore positive axillary nodes.NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in womenfollowing total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvantNOLVADEX therapy is likely to be beneficial.NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvantNOLVADEX therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated toreduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of thelabel). The decision regarding therapy with NOLVADEX for the reduction in breast cancerincidence should be based upon an individual assessment of the benefits and risks ofNOLVADEX therapy.Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patientswith breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk forbreast cancer. This effect was shown in a study of 5 years planned duration with a medianfollow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. Thelonger-term effects are not known. In this study, there was no impact of tamoxifen on overall orbreast cancer-related mortality (see BOXED WARNING at the beginning of the label).NOLVADEX is indicated only for high-risk women. âHigh riskâ is defined as women at least35 years of age with a 5-year predicted risk of breast cancer â¥ 1.67%, as calculated by the GailModel.Examples of combinations of factors predicting a 5-year risk â¥ 1.67% are:Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and ahistory of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of atleast one breast biopsy; or LCISAge 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at firstlive birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 oryounger; or One first degree relative with a history of breast cancer, and a personal history of a breastbiopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 oryounger; or One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 orolder and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at firstlive birth 30 or more.Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first livebirth 20 or older.Age 60 or older and: 5-year predicted risk of breast cancer â¥ 1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model isnecessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a GailModel Risk Assessment Tool by dialing 1-800-544-2007.There are insufficient data available regarding the effect of NOLVADEX on breast cancerincidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specificrecommendations on the effectiveness of NOLVADEX in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy withNOLVADEX for the reduction in breast cancer incidence should be based upon an individualassessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up periodof the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICALPHARMACOLOGY). DrugBank Targets: ¹⁶ 1. Estrogen receptor;2. Estrogen receptor beta;3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;4. Protein kinase C Mechanism of Action: ¹⁸ Target: estrogen receptors Action: competitor with estraidiol FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties inanimal test systems. The antiestrogenic effects may be related to its ability to compete withestrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of ratmammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression ofalready established DMBA-induced tumors. In this rat model, tamoxifen appears to exert itsantitumor effects by binding the estrogen receptors.In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol forestrogen receptor protein.

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

23214-92-8

31703

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2

50-18-0, 6055-19-2

2907

Docetaxel

Approved, Investigational

Phase 4,Phase 3,Phase 2

114977-28-5

148124

Epirubicin

Approved

Phase 4,Phase 3,Phase 2

56420-45-2

41867

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

31703

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Alkylating Agents

Phase 4,Phase 3,Phase 2

Antimitotic Agents

Phase 4,Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2

Antirheumatic Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2

Anastrozole

Approved, Investigational

Phase 3,Phase 2

120511-73-1

2187

Tamoxifen

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

10540-29-1

2733526

Carboplatin

Approved

Phase 2, Phase 3,Phase 3

41575-94-4

10339178 498142 38904

Progesterone

Approved, Vet_approved

Phase 3,Phase 2,Not Applicable,Early Phase 1

57-83-0

5994

Medroxyprogesterone acetate

Approved, Investigational

Phase 3

71-58-9

Fluorouracil

Approved

Phase 3,Phase 2

51-21-8

3385

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

126941

Exemestane

Approved, Investigational

Phase 3,Phase 2

107868-30-4

60198

Bevacizumab

Approved, Investigational

Phase 3,Phase 2

216974-75-3

Letrozole

Approved, Investigational

Phase 3,Phase 2,Not Applicable

112809-51-5

3902

Leuprolide

Approved, Investigational

Phase 3

53714-56-0

3911 657181

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1

33069-62-4

36314

Trastuzumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

180288-69-1

9903

Pertuzumab

Approved

Phase 3,Phase 2,Phase 1

145040-37-5, 380610-27-5

2540

Olaparib

Approved

Phase 2, Phase 3

763113-22-0

23725625

Metformin

Approved

Phase 3

657-24-9

14219 4091

Pembrolizumab

Approved

Phase 3,Early Phase 1

1374853-91-4

Menthol

Approved

Phase 3,Not Applicable

2216-51-5

16666

Oxybutynin

Approved, Investigational

Phase 3

5633-20-5

4634

Adenosine

Approved, Investigational

Phase 3

58-61-7

60961

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

77-92-9

311

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 3

58-05-9

143 6006

Lapatinib

Approved March 2007, Investigational

Phase 3,Phase 2,Not Applicable

231277-92-2, 388082-78-8

208908 9941095

Antineoplastic Agents, Hormonal

Phase 3,Phase 2,Phase 1,Not Applicable

Aromatase Inhibitors

Phase 3,Phase 2,Not Applicable

Bone Density Conservation Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Estrogen Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Estrogen Receptor Modulators

Phase 3,Phase 2,Phase 1,Not Applicable

Estrogens

Phase 3,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormones

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Selective Estrogen Receptor Modulators

Phase 3,Phase 2,Phase 1,Not Applicable

Steroid Synthesis Inhibitors

Phase 3,Phase 2,Not Applicable

Anti-Allergic Agents

Phase 3

Anti-Inflammatory Agents

Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 240)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®	Completed	NCT01448447	Phase 4
2	Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer	Completed	NCT00742222	Phase 4
3	An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer	Completed	NCT01660542	Phase 4	Neoadjuvant Chemotherapy with Docetaxel
4	Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery	Recruiting	NCT02627248	Phase 4	Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
5	Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator	Unknown status	NCT00321048	Phase 3
6	Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer	Completed	NCT01112254	Phase 3
7	Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy	Completed	NCT00053898	Phase 3	anastrozole;tamoxifen citrate
8	Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ	Completed	NCT00438659	Phase 3	mometasone furoate
9	Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions	Completed	NCT00262899	Phase 3
10	RAPID: Randomized Trial of Accelerated Partial Breast Irradiation	Completed	NCT00282035	Phase 3
11	Intraoperative Gamma Camera for Breast Cancer Surgery	Completed	NCT00757302	Phase 3
12	Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer	Completed	NCT00026286	Phase 3	conjugated estrogens;medroxyprogesterone
13	Study of Docetaxel in Breast Cancer Patients	Completed	NCT00174707	Phase 3	epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
14	S9630, Medroxyprogesterone in Treating Women With Breast Cancer	Completed	NCT00002920	Phase 3	medroxyprogesterone;tamoxifen citrate
15	Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer	Completed	NCT00374322	Phase 3	lapatinib
16	Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer	Completed	NCT00038467	Phase 3	Tamoxifen;Exemestane
17	Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane	Completed	NCT00036270	Phase 3	exemestane (Aromasin);tamoxifen + exemestane
18	BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer	Completed	NCT00528567	Phase 3	Bevacizumab;Standard adjuvant chemotherapy
19	Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer	Completed	NCT02980965	Phase 3	letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
20	Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women	Completed	NCT00003906	Phase 3	Raloxifene;Tamoxifen
21	Management of Low-risk DCIS	Recruiting	NCT02492607	Phase 3
22	CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer	Recruiting	NCT02918084	Phase 3	Anastrozole or Letrozole or Exemestane;Anastrozole or Letrozole or Exemestane
23	Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer	Recruiting	NCT03150576	Phase 2, Phase 3	Olaparib;Paclitaxel and Carboplatin
24	Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer	Recruiting	NCT01905046	Phase 3	metformin hydrochloride
25	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)	Recruiting	NCT03036488	Phase 3	Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
26	Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	Active, not recruiting	NCT00769379	Phase 3
27	Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)	Active, not recruiting	NCT00907868	Phase 3
28	Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast	Active, not recruiting	NCT00470236	Phase 3
29	Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ	Active, not recruiting	NCT00072462	Phase 3	tamoxifen citrate;Anastrozole
30	Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ	Active, not recruiting	NCT00003857	Phase 3	tamoxifen citrate
31	APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer	Active, not recruiting	NCT00402519	Phase 3
32	Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia	Active, not recruiting	NCT01357772	Phase 3	Tamoxifen;placebo
33	Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients	Active, not recruiting	NCT02772731	Phase 3
34	A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer	Active, not recruiting	NCT01358877	Phase 3	5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
35	Oxybutynin Chloride in Managing Hot Flashes	Active, not recruiting	NCT02961790	Phase 3	Oxybutynin Chloride
36	A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	Active, not recruiting	NCT01566721	Phase 3	Herceptin
37	Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer	Active, not recruiting	NCT00878709	Phase 3	neratinib
38	A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive	Active, not recruiting	NCT01966471	Phase 3	Trastuzumab Emtansine;Trastuzumab;Pertuzumab;Paclitaxel;Epirubicin;Doxorubicin;Docetaxel;Cyclophosphamide;5-Fluorouracil
39	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer	Active, not recruiting	NCT01272037	Phase 3	Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
40	Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery	Active, not recruiting	NCT01349322	Phase 3
41	A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)	Active, not recruiting	NCT01772472	Phase 3	trastuzumab;trastuzumab emtansine
42	Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer	Enrolling by invitation	NCT03580395	Phase 2, Phase 3	Apatinib;paclitaxel;cisplatin
43	A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients	Not yet recruiting	NCT03561740	Phase 3	capecitabine
44	Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS	Withdrawn	NCT00324714	Phase 3	risedronate sodium
45	Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)	Unknown status	NCT00669747	Phase 2	Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
46	Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole	Unknown status	NCT00077168	Phase 2	anastrozole;tamoxifen citrate
47	Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer	Unknown status	NCT01175694	Phase 2
48	Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland	Unknown status	NCT01630226	Phase 2	Neoadjuvant Cisplatin Chemotherapy
49	Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors	Unknown status	NCT02150525	Phase 2
50	Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors	Unknown status	NCT01849250	Phase 2	Docosahexaenoic Acid

Search NIH Clinical Center for Ductal Carcinoma in Situ

Sources

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

#	Genetic test	Affiliating Genes
1	Ductal Carcinoma in Situ ²⁹

Sources

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

⁴¹

Breast, Lymph Node, Testes, Bone, Skin, Liver, Prostate

Sources

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 905)

#	Title	Authors	Year
1	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )	Miligy I.M....Rakha E.A.	2018
2	The PPARI^ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. ( 29350308 )	Ory V....Riegel A.T.	2018
3	Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. ( 29973218 )	Zubeldia-Plazaola A....Fuster G.	2018
4	Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. ( 29759643 )	De Lorenzi F....Galimberti V.	2018
5	Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. ( 29398498 )	Shi B....Lo J.Y.	2018
6	Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report. ( 29977557 )	Reinhardt F....Mohrmann S.	2018
7	Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. ( 29428007 )	Levinsohn E....Chagpar A.B.	2018
8	Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. ( 29383628 )	Hwang K.T....Kim Y.A.	2018
9	The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. ( 29417425 )	Hart V....Sprague B.L.	2018
10	Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature. ( 29798815 )	DA^ria M.T....Filassi J.R.	2018
11	Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. ( 29632058 )	Hassett M.J....Punglia R.S.	2018
12	Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery? ( 29773535 )	Bagenal J....Dodwell D.	2018
13	Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. ( 29593431 )	Wu S.G....He Z.Y.	2018
14	Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. ( 29271113 )	Huang N.S....Wu J.	2018
15	Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. ( 29439886 )	Shumway D.A....Jagsi R.	2018
16	Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ-Reply. ( 29344613 )	Lum S.S....Chavez de Paz Villanueva C.	2018
17	A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. ( 29445939 )	Giannakeas V....Narod S.A.	2018
18	Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. ( 29322827 )	De Rose F....Scorsetti M.	2018
19	Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )	Beguinot M....Radosevic-Robin N.	2018
20	Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. ( 29730730 )	Wadsten C....Sund M.	2018
21	Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. ( 29786772 )	Watanabe Y....Mitsuyama S.	2018
22	Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data. ( 29669162 )	Hirth J.M....Kuo Y.F.	2018
23	Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ. ( 29344621 )	Grimm L.J....Hyslop T.	2018
24	Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: Analysis of Surveillance, Epidemiology, and End Results data. ( 29804045 )	You Q....Yu F.	2018
25	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. ( 29398324 )	Maxwell A.J....Thompson A.M.	2018
26	Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. ( 29709458 )	Kuo S.H....Huang C.S.	2018
27	Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ. ( 29694611 )	Chade M.C....Medeiros E.M.	2018
28	Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. ( 29207971 )	Ko H....Song Y.M.	2017
29	Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. ( 28894982 )	Gregorowitsch M.L....Verkooijen H.M.	2017
30	Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. ( 28330493 )	Sarper M....Jones J.L.	2017
31	Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. ( 28415667 )	Huang X.Z....Wu J.	2017
32	(18)F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation. ( 28781782 )	Fujii T....Kuwano H.	2017
33	Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan. ( 28090007 )	Tozaki M....Arai M.	2017
34	Patient-reported outcomes in ductal carcinoma in situ: A systematic review. ( 27987454 )	King M.T....Rutherford C.	2017
35	Performance characteristics of specimen radiography for margin assessment for ductal carcinoma in situ: a systematic review. ( 28831674 )	Versteegden D.P.A....Strobbe L.J.A.	2017
36	Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer. ( 28819437 )	Shen S.C....Chen S.C.	2017
37	Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFI^ signaling. ( 28512126 )	Lo P.K....Zhou Q.	2017
38	Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis. ( 29325859 )	Poulakaki N....Sergentanis T.N.	2017
39	Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. ( 28506312 )	Sameni M....Sloane B.F.	2017
40	Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. ( 29214316 )	Richards C.A....Hershman D.L.	2017
41	Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment. ( 28914599 )	Luo J....Rahbar H.	2017
42	Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. ( 27871025 )	Mathew J....Bello A.M.	2017
43	Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma? ( 28911076 )	Van Bockstal M....Pinder S.	2017
44	Trends in the use of implantable accelerated partial breast irradiation for ductal carcinoma in situ: Implications of the recent amendments to the American Society for Radiation Oncology consensus guidelines. ( 28063816 )	Haque W....Teh B.S.	2017
45	The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. ( 29096155 )	Holm-Rasmussen E.V....Tvedskov T.F.	2017
46	Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. ( 28885232 )	Bosch D.E....Chang O.H.	2017
47	Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No? ( 28862116 )	Stoleru L.S....Stoleru S.	2017
48	Availability of immunocytochemistry using cocktail antibody targeting p63/cytokeratin14 for the differential diagnosis of fibroadenoma and ductal carcinoma in situ in fine needle aspiration cytology of the breast. ( 28685877 )	Maeda I....Takagi M.	2017
49	SOX11 promotes invasive growth and ductal carcinoma in situ progression. ( 28707729 )	Oliemuller E....Howard B.A.	2017
50	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. ( 28338653 )	Pang J.B....Fox S.B.	2017

Sources

Genes for Ductal Carcinoma in Situ

Genes related to Ductal Carcinoma in Situ (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	30.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	27.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	ESR1	Estrogen Receptor 1	Protein Coding	26.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	PGR	Progesterone Receptor	Protein Coding	26.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	EGFR	Epidermal Growth Factor Receptor	Protein Coding	24.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	TP53	Tumor Protein P53	Protein Coding	24.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	KRT5	Keratin 5	Protein Coding	24.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	BRCA1	BRCA1, DNA Repair Associated	Protein Coding	23.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	KRT14	Keratin 14	Protein Coding	23.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	BRCA2	BRCA2, DNA Repair Associated	Protein Coding	23.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CCND1	Cyclin D1	Protein Coding	23.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CDH1	Cadherin 1	Protein Coding	23.45	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	22.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	22.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	22.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	KRT8	Keratin 8	Protein Coding	22.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	AR	Androgen Receptor	Protein Coding	22.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	CLDN7	Claudin 7	Protein Coding	19.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
19	S100A7	S100 Calcium Binding Protein A7	Protein Coding	13.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	PIP	Prolactin Induced Protein	Protein Coding	12.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

⁹

(show all 44)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM6005476	ZFHX3	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.2403A>T	p.K801N	16:72957743-72957743	7
2	COSM10656	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.742C>T	p.R248W	17:7674221-7674221	7
3	COSM43559	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.517G>T	p.V173L	17:7675095-7675095	7
4	COSM10701	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.824G>T	p.C275F	17:7673796-7673796	7
5	COSM10867	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.797G>A	p.G266E	17:7673823-7673823	7
6	COSM44415	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.711G>C	p.M237I	17:7674252-7674252	7
7	COSM44737	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.860A>G	p.E287G	17:7673760-7673760	7
8	COSM6932	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.733G>A	p.G245S	17:7674230-7674230	7
9	COSM10662	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.743G>A	p.R248Q	17:7674220-7674220	7
10	COSM10779	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.818G>T	p.R273L	17:7673802-7673802	7
11	COSM43714	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.836G>A	p.G279E	17:7673784-7673784	7
12	COSM44901	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.532C>G	p.H178D	17:7675080-7675080	7
13	COSM10660	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.818G>A	p.R273H	17:7673802-7673802	7
14	COSM43814	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.587G>C	p.R196P	17:7674944-7674944	7
15	COSM11089	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.584T>C	p.I195T	17:7674947-7674947	7
16	COSM6906973	SMARCA4	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1111G>T	p.E371*	19:10987917-10987917	7
17	COSM6906974	PPP2R1A	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.510C>A	p.F170L	19:52212692-52212692	7
18	COSM775	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.3140A>G	p.H1047R	3:179234297-179234297	7
19	COSM12458	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1634A>C	p.E545A	3:179218304-179218304	7
20	COSM776	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.3140A>T	p.H1047L	3:179234297-179234297	7
21	COSM760	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1624G>A	p.E542K	3:179218294-179218294	7
22	COSM774	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.3139C>T	p.H1047Y	3:179234296-179234296	7
23	COSM763	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1633G>A	p.E545K	3:179218303-179218303	7
24	COSM754	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1035T>A	p.N345K	3:179203765-179203765	7
25	COSM580	NRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.181C>A	p.Q61K	1:114713909-114713909	7
26	COSM565	NRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.35G>C	p.G12A	1:114716126-114716126	7
27	COSM6057047	NOTCH1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.7372C>T	p.P2458S	9:136496367-136496367	7
28	COSM6005481	MAP2K2	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.931G>T	p.D311Y	19:4097332-4097332	7
29	COSM521	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.35G>A	p.G12D	12:25245350-25245350	7
30	COSM532	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.38G>A	p.G13D	12:25245347-25245347	7
31	COSM516	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.34G>T	p.G12C	12:25245351-25245351	7
32	COSM520	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.35G>T	p.G12V	12:25245350-25245350	7
33	COSM1179671	KMT2C	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.925C>T	p.P309S	7:152273792-152273792	7
34	COSM4595028	KMT2C	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.2681G>A	p.R894Q	7:152235905-152235905	7
35	COSM6057048	HRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.148A>G	p.T50A	11:533908-533908	7
36	COSM6906971	H3F3A	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.218G>A	p.R73Q	1:226065745-226065745	7
37	COSM48358	ERBB2	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.929C>T	p.S310F	17:39711955-39711955	7
38	COSM14060	ERBB2	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.2264T>C	p.L755S	17:39723967-39723967	7
39	COSM19786	CDH1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.779C>T	p.P260L	16:68810288-68810288	7
40	COSM6057049	AKT1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.61A>G	p.T21A	14:104780202-104780202	7
41	COSM33765	AKT1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.49G>A	p.E17K	14:104780214-104780214	7
42	COSM5174142		breast,NS,carcinoma in situ,ductal carcinoma in situ	c.884C>T	p.S295F	17:39711955-39711955	7
43	COSM6906972		breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1111G>T	p.E371*	19:10987917-10987917	7
44	COSM6964823		breast,NS,carcinoma in situ,ductal carcinoma in situ	c.659C>T	p.T220M	1:39897898-39897898	7

Sources

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Sources

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 66)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.9	AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.76	AKT1 BRCA1 BRCA2 CCND1 EGFR ERBB2
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.39	AKT1 CCND1 EGFR ERBB2 MUC1 PTGS2
4	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	13	AKT1 BRCA1 CCND1 EGFR ERBB2 PTGS2
5	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.8	AKT1 AR BRCA2 CCND1 CDH1 EGFR
6	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.75	AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
7	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.73	BRCA1 BRCA2 CCND1 ESR1 TP53
8	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.58	AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
9	Pathways in cancer ³⁷	12.58	AKT1 AR BRCA2 CCND1 CDH1 EGFR
10	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.52	AKT1 CCND1 EGFR ERBB2 TP53
11	MicroRNAs in cancer ³⁷	12.52	BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
12	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.46	AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
13	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.42	AKT1 BRCA1 ESR1 PTGS2
14	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.33	AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
15	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.32	AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
16	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.29	AKT1 BRCA1 CCND1 TP53
17	Proteoglycans in cancer ³⁷	12.28	AKT1 CCND1 EGFR ERBB2 ESR1 TP53
18	Cell cycle Role of SCF complex in cell cycle regulation ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Regulation of G1/S transition (part 1) ²² Immune response MIF-JAB1 signaling ²²	12.26	BRCA1 CCND1 ESR1 PGR
19	AKT Signaling Pathway ⁶⁷	12.19	AKT1 CCND1 EGFR ERBB2 TP53
20	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.12	AKT1 AR CCND1 EGFR ERBB2
21	Hepatitis C ³⁷	12.11	AKT1 CLDN7 EGFR TP53
22	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ RAS signaling downstream of NF1 loss-of-function variants ⁶⁶	12.1	AKT1 CCND1 EGFR ERBB2
23	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.09	CCND1 EGFR ERBB2
24	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	12.08	AKT1 EGFR ERBB2 TP53
25	Spinal Cord Injury ¹	12.06	CCND1 EGFR PTGS2 TP53
26	Colorectal Cancer Metastasis ⁶⁴	12.06	AKT1 CCND1 CDH1 EGFR PTGS2 TP53
27	Cell cycle Cell cycle (generic schema) ²² Show member pathways Cell cycle Regulation of G1/S transition (part 2) ²² G0 and Early G1 ⁶⁶ G2 Phase ⁶⁶	12.03	AKT1 CCND1 CDH1 PTGS2 TP53
28	Thyroid hormone signaling pathway ³⁷	12.03	AKT1 CCND1 ESR1 TP53
29	DNA Damage Response (only ATM dependent) ¹	12.02	AKT1 CCND1 ERBB2 TP53
30	Glioblastoma Multiforme ⁶⁴	12	AKT1 CCND1 EGFR TP53
31	Interleukin-4 and 13 signaling ⁶⁶	12	AKT1 CCND1 MUC1 PTGS2 TP53
32	UVA-Induced MAPK Signaling ⁶⁴ Show member pathways UVB-Induced MAPK Signaling ⁶⁴	11.98	AKT1 EGFR TP53
33	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.98	EGFR ERBB2 ESR1 PGR
34	Small cell lung cancer ³⁷	11.91	AKT1 CCND1 PTGS2 TP53
35	Glucocorticoid receptor regulatory network ¹	11.84	AKT1 KRT14 KRT5 TP53
36	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.83	BRCA1 BRCA2 TP53
37	Androgen receptor signaling pathway ¹	11.83	AKT1 AR BRCA1 CCND1 EGFR
38	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.8	AR CCND1 CDH1
39	Regulation of nuclear SMAD2/3 signaling ¹	11.79	AKT1 AR ESR1
40	Platinum drug resistance ³⁷	11.78	AKT1 BRCA1 ERBB2 TP53
41	Adherens junction ³⁷	11.76	CDH1 EGFR ERBB2
42	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.74	CCND1 EGFR ESR1
43	Association Between Physico-Chemical Features and Toxicity Associated Pathways ¹	11.73	AKT1 EGFR ERBB2
44	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.73	AKT1 BRCA1 ERBB2 TP53
45	Regulation of Telomerase ¹	11.72	AKT1 CCND1 EGFR ESR1
46	Central carbon metabolism in cancer ³⁷	11.71	AKT1 EGFR ERBB2 TP53
47	Validated targets of C-MYC transcriptional repression ¹	11.67	BRCA1 CCND1 ERBB2 S100A7
48	Bladder cancer ³⁷ ¹	11.67	CCND1 CDH1 EGFR ERBB2 TP53
49	Coregulation of Androgen receptor activity ¹	11.63	AKT1 AR BRCA1 CCND1
50	Copper homeostasis ¹	11.62	AKT1 CCND1 TP53

Sources

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.89	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2	nuclear chromatin	GO:0000790	9.56	AR ESR1 MUC1 TP53
3	protein-containing complex	GO:0032991	9.23	AKT1 AR BRCA1 BRCA2 EGFR ESR1
4	nucleus	GO:0005634	10.06	AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 38)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cell proliferation	GO:0042127	9.98	BRCA1 BRCA2 EGFR PTGS2
2	cytokine-mediated signaling pathway	GO:0019221	9.95	AKT1 CCND1 MUC1 PTGS2 TP53
3	transcription initiation from RNA polymerase II promoter	GO:0006367	9.9	AR CCND1 ESR1 PGR
4	positive regulation of protein phosphorylation	GO:0001934	9.89	AKT1 CCND1 EGFR ERBB2
5	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.85	AKT1 EGFR PTGS2
6	positive regulation of gene expression	GO:0010628	9.85	AKT1 AR BRCA1 ERBB2 PIP TP53
7	positive regulation of cell growth	GO:0030307	9.83	AKT1 EGFR ERBB2
8	cellular response to mechanical stimulus	GO:0071260	9.83	AKT1 EGFR PTGS2
9	response to estrogen	GO:0043627	9.81	BRCA1 CCND1 ESR1
10	steroid hormone mediated signaling pathway	GO:0043401	9.81	AR ESR1 PGR
11	cell proliferation	GO:0008283	9.8	AKT1 AR BRCA2 EGFR ERBB2 TP53
12	positive regulation of smooth muscle cell proliferation	GO:0048661	9.79	AKT1 EGFR PTGS2
13	cellular response to growth factor stimulus	GO:0071363	9.78	AKT1 EGFR ERBB2
14	epidermis development	GO:0008544	9.78	EGFR KRT14 KRT5 S100A7
15	response to estradiol	GO:0032355	9.76	CCND1 EGFR ESR1 PTGS2
16	positive regulation of transcription, DNA-templated	GO:0045893	9.76	AKT1 AR BRCA1 BRCA2 CDH1 EGFR
17	cellular response to epidermal growth factor stimulus	GO:0071364	9.75	AKT1 EGFR ERBB2
18	response to organic substance	GO:0010033	9.73	AKT1 CCND1 CDH1 PTGS2
19	positive regulation of vasoconstriction	GO:0045907	9.69	AKT1 EGFR PTGS2
20	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.67	ESR1 TP53
21	hemidesmosome assembly	GO:0031581	9.67	KRT14 KRT5
22	Leydig cell differentiation	GO:0033327	9.66	AR CCND1
23	positive regulation of transcription by RNA polymerase III	GO:0045945	9.66	AR ERBB2
24	mitotic G1 DNA damage checkpoint	GO:0031571	9.65	CCND1 TP53
25	positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	GO:0031659	9.63	AKT1 EGFR
26	prostate gland growth	GO:0060736	9.62	AR CYP19A1
27	cellular response to indole-3-methanol	GO:0071681	9.58	BRCA1 CDH1
28	response to X-ray	GO:0010165	9.58	BRCA2 CCND1 TP53
29	chordate embryonic development	GO:0043009	9.57	BRCA1 BRCA2
30	morphogenesis of an epithelial fold	GO:0060571	9.56	AR EGFR
31	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.49	AR PGR
32	mammary gland alveolus development	GO:0060749	9.43	AR CCND1 ESR1
33	response to UV-A	GO:0070141	9.13	AKT1 CCND1 EGFR
34	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	8.92	BRCA1 BRCA2 MUC1 TP53
35	positive regulation of transcription by RNA polymerase II	GO:0045944	10.16	AKT1 AR BRCA1 EGFR ESR1 PGR
36	cellular response to DNA damage stimulus	GO:0006974	10.04	AKT1 BRCA1 BRCA2 CCND1 TP53
37	negative regulation of apoptotic process	GO:0043066	10.01	AKT1 CLDN7 EGFR ERBB2 PTGS2 TP53
38	positive regulation of cell proliferation	GO:0008284	10	AKT1 AR CCND1 CLDN7 EGFR PTGS2

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.88	AKT1 CCND1 EGFR ESR1 TP53
2	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.83	AR ESR1 MUC1 PGR TP53
3	identical protein binding	GO:0042802	9.81	AKT1 BRCA2 CDH1 CLDN7 EGFR ERBB2
4	beta-catenin binding	GO:0008013	9.72	AR CDH1 ESR1
5	ATPase binding	GO:0051117	9.71	AR ESR1 PGR
6	protein phosphatase binding	GO:0019903	9.67	EGFR ERBB2 TP53
7	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.63	EGFR ERBB2 ESR1
8	steroid hormone receptor activity	GO:0003707	9.58	AR ESR1 PGR
9	nuclear receptor activity	GO:0004879	9.54	AR ESR1 PGR
10	obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity	GO:0004716	9.51	EGFR ERBB2
11	steroid binding	GO:0005496	9.5	AR ESR1 PGR
12	enzyme binding	GO:0019899	9.28	AKT1 AR BRCA1 CCND1 EGFR ESR1
13	nitric-oxide synthase regulator activity	GO:0030235	9.13	AKT1 EGFR ESR1
14	protein binding	GO:0005515	10.23	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15	zinc ion binding	GO:0008270	10	AR BRCA1 ESR1 PGR S100A7 TP53

Sources

Sources for Ductal Carcinoma in Situ

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia